Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema patients learn to Self-Inject in new study

NCT ID NCT06224192

Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether teenagers and adults with moderate-to-severe eczema (atopic dermatitis) could successfully give themselves injections of the drug rocatinlimab at home using special devices. The main goal was to see how many full doses were self-administered correctly up to 16 weeks. The study involved 151 participants and was completed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

151 people

The number who actually took part.

Started

Apr 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 12 at Day 1. * Diagnosis of AD according to American Academy of Dermatology (AAD) Consensus Criteria (2014) that has been present for at least 12 months. * History of inadequate response to Topical Corticosteroids (TCS) of medium to higher potency (with or without topical calcineurin inhibitors \[TCI\]). * Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) score ≥ 3 at screening and pre-randomization. * Eczema Area and Severity Index (EASI) score ≥ 16 at initial at screening and pre-randomization. * ≥ 10% body surface area (BSA) of AD involvement at screening and pre-randomization. Exclusion Criteria: * Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to day 1 pre-randomization. * Treatment with any of the following medications or therapies within 5 half-lives prior to day 1 pre-randomization: 1. Systemic corticosteroids 2. Non-biologic, non-targeted systemic immunosuppressants 3. Oral or Topical Janus kinase inhibitors * Treatment with any of the following medications or therapies within 1 week before day 1 pre-randomization: 1. Topical phosphodiesterase 4 (PDE4) inhibitors 2. Other topical immunosuppressive agents (not including TCS/TCI) 3. Combination topical agents containing any of the above components

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Ajou University Hospital

    Suwon-si, Gyeonggi-do, 16499, South Korea

  • Allergy Research Canada Incorporated

    Niagara Falls, Ontario, L2H 1H5, Canada

  • Alliance Clinical Trials

    Waterloo, Ontario, N2J 1C4, Canada

  • Anchor Medical Research

    Miami, Florida, 33176, United States

  • Apex Clinical Research Center LLC

    Mayfield Heights, Ohio, 44124, United States

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Bexley Dermatology Research

    Bexley, Ohio, 43209, United States

  • Cumberland Skin Center

    Hermitage, Tennessee, 37076, United States

  • DermEdge Research Incorporated

    Mississauga, Ontario, L4Y 4C5, Canada

  • Dermatology Ottawa Research Centre

    Ottawa, Ontario, K2C 3N2, Canada

  • Dermatology Research Associates

    Los Angeles, California, 90045, United States

  • Dermatology and Ophthalmology Kume Clinic

    Sakai-shi, Osaka, 593-8324, Japan

  • Dermatology and Skin Cancer Center Leawood

    Leawood, Kansas, 66211, United States

  • Direct Helpers Research Center

    Hialeah, Florida, 33012, United States

  • Ekihigashi Dermatology Allergy Clinic

    Fukuoka, Fukuoka, 812-0013, Japan

  • Essential Medical Research LLC

    Tulsa, Oklahoma, 74137, United States

  • Excel Clinical Research

    Las Vegas, Nevada, 89109, United States

  • FACET Dermatology

    Toronto, Ontario, M4E 1R7, Canada

  • Fukuoka University Hospital

    Fukuoka, Fukuoka, 814-0180, Japan

  • Hallym University Kangnam Sacred Heart Hospital

    Seoul, 07441, South Korea

  • Hamilton Research, LLC

    Alpharetta, Georgia, 30022, United States

  • Havana Research Institute Inc

    Pasadena, California, 91105, United States

  • Health Concepts

    Rapid City, South Dakota, 57702, United States

  • Integrative Skin Science and Research

    Sacramento, California, 95815, United States

  • Interior Dermatology Centre

    Kelowna, British Columbia, V1W 4V5, Canada

  • Keio University Hospital

    Shinjuku-ku, Tokyo, 160-8582, Japan

  • Kern Research Inc

    Bakersfield, California, 93301, United States

  • Korea University Ansan Hospital

    Ansan-si, Gyeonggi-do, 15355, South Korea

  • Kyung Hee University Hospital at Gangdong

    Seoul, 05278, South Korea

  • LEADER Research

    Hamilton, Ontario, L8L 3C3, Canada

  • Las Vegas Clinical Trials

    North Las Vegas, Nevada, 89030, United States

  • Long Beach Research Institute

    Long Beach, California, 90805, United States

  • Lynderm Research Inc

    Markham, Ontario, L3P 1X3, Canada

  • Matsuo Clinic

    Fukuoka, Fukuoka, 819-0373, Japan

  • Mita Dermatology Clinic

    Minato-ku, Tokyo, 108-0014, Japan

  • North Bay Dermatology Centre

    North Bay, Ontario, P1B 3Z7, Canada

  • Severance Hospital Yonsei University Health System

    Seoul, 03722, South Korea

  • Skin Cancer and Dermatology Institute

    Reno, Nevada, 89509, United States

  • Skinsense Medical Research

    Saskatoon, Saskatchewan, S7K 2C1, Canada

  • Sms Clinical Research Limited Liability Company

    Mesquite, Texas, 75149, United States

  • Suizenji Dermatology Clinic

    Kumamoto, Kumamoto, 862-0950, Japan

  • Texas Dermatology Research Center

    Plano, Texas, 75025, United States

  • The Catholic University of Korea Seoul St Marys Hospital

    Seoul, 06591, South Korea

  • The Skin Surgery Center for Clinical Research

    Winston-Salem, North Carolina, 27103, United States

  • Treasure Valley Medical Research

    Boise, Idaho, 83706, United States

  • Virginia Dermatology and Skin Cancer Center

    Norfolk, Virginia, 23502, United States

  • XLR8 Medical Research, Incorporated

    Windsor, Ontario, N8T 1E6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.